All In Biotech

Drug Trial Radar · NCT04485195

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Jun 17, 2021

Primary completion

Sep 15, 2024

Study completion Nov 6, 2024

Sponsor

Lead sponsor
Ottawa Hospital Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to compare IV vernakalant to IV procainamide for the ED management of acute AF patients. If vernakalant proves to be more effective, faster, and safer than IV procainamide, this will give clinicians an important alternative for pharmacological cardioversion of acute AF. The investigators propose a pragmatic comparative effectiveness trial entailing an open label, randomized controlled trial at 12 large Canadian EDs. Study subjects will be randomized to 1 of 2 treatment arms: 1) Patients will receive an initial infusion of 3mg/kg of IV vernakalant over 10 minutes, followed by a second dose of 2mg/kg over 10 minutes, if necessary, or 2) Patients will receive a continuous infusion of 15mg/kg of IV procainamide over 60 minutes. The primary aim will be to compare conversion to normal sinus rhythm between the two drugs. The investigators will include stable patients presenting with an episode of acute AF of at least 3 hours duration, where symptoms require urgent management and where immediate cardioversion is a reasonable option. Using the integrated consent model, research assistants will obtain verbal consent from eligible patients.

Conditions

  • Atrial Fibrillation

Interventions

  • VernakalantDrug

    an initial infusion of 3 mg/kg infused over a 10-minute period by a pre-programmed IV pump

  • ProcainamideDrug

    15 mg/kg in 500 mL of normal saline given over 60 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Conversion to sinus rhythm for a minimum duration of 30 minutesTime frame: During any time following randomization until 30 minutes past the completion of the drug infusion

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada

  • Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Hamilton Health Sciences Centre

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • Ottawa Hospital

    Ottawa, Ontario, Canada

  • St. Michaels

    Toronto, Ontario, Canada

  • Sunnybrook Hospital

    Toronto, Ontario, Canada

  • Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval

    Laval, Quebec, Canada

  • Montreal Heart Institute

    Montreal, Quebec, Canada

  • Hopital Du Sacre-Coeur

    Montreal, Quebec, Canada

  • Hopital de L'Enfant-Jesus

    Québec, Quebec, Canada

  • Hôtel-Dieu de Lévis

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.